A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02

The purpose of this study is to evaluate the safety and tolerability of long-term dosing with
ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

本研究旨在评估转甲状腺素蛋白（transthyretin, TTR）介导的淀粉样变性（ATTR）患者长期接受ALN-TTR02（patisiran，帕迪西兰）给药的安全性与耐受性。